Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.

Petru E, Singer CF, Polterauer S, Galid A, Schauer C, Klocker J, Seifert M, Reinthaller A, Benedicic C, Hubalek M, Hefler L, Marth C, Scholl-Firon T, Bogner G, Zeimet AG.

Wien Med Wochenschr. 2015 Oct;165(19-20):387-94. doi: 10.1007/s10354-015-0392-3. Epub 2015 Oct 15. Review.

PMID:
26471371
2.

Activity of T-DM1 in Her2-positive breast cancer brain metastases.

Bartsch R, Berghoff AS, Vogl U, Rudas M, Bergen E, Dubsky P, Dieckmann K, Pinker K, Bago-Horvath Z, Galid A, Oehler L, Zielinski CC, Gnant M, Steger GG, Preusser M.

Clin Exp Metastasis. 2015 Oct;32(7):729-37. doi: 10.1007/s10585-015-9740-3. Epub 2015 Aug 25.

PMID:
26303828
3.

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF; Austrian Breast and Colorectal Cancer Study Group.

Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31.

PMID:
26040499
4.

A final analysis from the CHOICE study examining darbepoetin alfa use for chemotherapy-induced anaemia in current European clinical practice.

Van Belle S, Swieboda-Sadlej A, Karanikiotis C, Labourey JL, Galid A, Wheeler T, Pujol B, Aerts JG.

Curr Med Res Opin. 2012 Jul;28(7):1079-87. doi: 10.1185/03007995.2012.698601. Epub 2012 Jun 21.

PMID:
22642867
5.

Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study.

Aerts JG, Swieboda-Sadlej A, Karanikiotis C, Labourey JL, Galid A, Wheeler T, Pujol B, Van Belle S.

Curr Med Res Opin. 2012 Jul;28(7):1089-99. doi: 10.1185/03007995.2012.698602. Epub 2012 Jun 21.

PMID:
22642866
6.

Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy - data from the CHOICE study.

Van Belle S, Karanikiotis C, Labourey JL, Galid A, Wheeler T, Pujol B.

Curr Med Res Opin. 2011 May;27(5):987-94. doi: 10.1185/03007995.2011.562493. Epub 2011 Mar 9.

PMID:
21385113
7.

Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.

Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Nader A, Stierer M, Gnant MF; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2009 Sep 15;15(18):5888-94. doi: 10.1158/1078-0432.CCR-09-0728. Epub 2009 Sep 1.

8.

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R; ABCSG-12 Trial Investigators, Marth C.

N Engl J Med. 2009 Feb 12;360(7):679-91. doi: 10.1056/NEJMoa0806285. Erratum in: N Engl J Med. 2009 May 28;360(22):2379.

9.

Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.

Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2008 Apr 1;14(7):2082-7. doi: 10.1158/1078-0432.CCR-07-2068.

10.

Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.

Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant MF, Filipits M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2008 Mar 15;14(6):1767-74. doi: 10.1158/1078-0432.CCR-07-4122.

11.

Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).

Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R; Austrian Breast, Colorectal Cancer Study Group (ABCSG).

Breast Cancer Res Treat. 2008 Nov;112(1):203-13. Epub 2007 Dec 22.

PMID:
18158620
12.

Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.

Steger GG, Galid A, Gnant M, Mlineritsch B, Lang A, Tausch C, Rudas M, Greil R, Wenzel C, Singer CF, Haid A, Pöstlberger S, Samonigg H, Luschin-Ebengreuth G, Kwasny W, Klug E, Kubista E, Menzel C, Jakesz R; ABCSG-14.

J Clin Oncol. 2007 May 20;25(15):2012-8.

PMID:
17513805
13.

Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.

Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R; Austrian Breast and Colorectal Cancer Study Group.

J Clin Oncol. 2007 Mar 1;25(7):820-8. Epub 2006 Dec 11.

PMID:
17159195
14.

Axillary lymph node metastases in patients with breast carcinomas: assessment with nonenhanced versus uspio-enhanced MR imaging.

Memarsadeghi M, Riedl CC, Kaneider A, Galid A, Rudas M, Matzek W, Helbich TH.

Radiology. 2006 Nov;241(2):367-77.

PMID:
17057065
15.

Polymorphisms of the endothelial nitric oxide synthase gene in women with vulvar cancer.

Riener EK, Hefler LA, Grimm C, Galid A, Zeillinger R, Tong-Cacsire D, Gitsch G, Leodolter S, Tempfer CB.

Gynecol Oncol. 2004 Jun;93(3):686-90.

PMID:
15196865
16.

Pharmacological modulation of local feedback mechanisms as a therapeutic approach in breast cancer treatment.

Singer CF, Hudelist G, Galid A, Kubista E.

Drugs Today (Barc). 2003 Dec;39(12):917-26. Review.

PMID:
14747837
17.

Impact of pretreatment thrombocytosis on survival in primary breast cancer.

Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M, Tausch C, Galid A, Steger G, Jakesz R; Austrian Breast and Colorectal Cancer Study Group.

Thromb Haemost. 2003 Jun;89(6):1098-106.

PMID:
12783124
18.

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.

Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ; International Pegfilgrastim 749 Study Group.

Ann Oncol. 2003 Jan;14(1):29-35.

PMID:
12488289
19.

The oestrogen receptor and its selective modulators in gynaecological oncology.

Seifert M, Galid A, Kubista E.

Eur J Cancer. 2000 Sep;36 Suppl 4:S66-7. No abstract available.

PMID:
11056325
20.

Estrogen replacement therapy in women with a history of breast cancer.

Seifert M, Galid A, Kubista E.

Maturitas. 1999 Jun 21;32(2):63-8. Review.

PMID:
10465373

Supplemental Content

Loading ...
Support Center